Brenig Therapeutics announced the initiation of the first-in-human clinical trial for BT-267, a best-in-class LRRK2 inhibitor developed as a potential disease-modifying treatment for idiopathic and ...
Deep Learning Technology Outperforms Traditional Methods in Biomedical Image Segmentation PHILADELPHIA, Nov. 25, 2024 /PRNewswire/ -- Researchers at Children's Hospital of Philadelphia (CHOP) ...